The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia.....           Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia.....           Bayer gets Japanese approval for Gadovist injection.....           Bayer gets Japanese approval for Gadovist injection.....           Genentech project to add 100 jobs.....           Genentech project to add 100 jobs.....           Orexigen's Mysimba catches up to Saxenda at EMA finish line.....           Orexigen's Mysimba catches up to Saxenda at EMA finish line.....           Novo Nordisk's Tresiba news a black cloud for Sanofi's new CEO.....           Novo Nordisk's Tresiba news a black cloud for Sanofi's new CEO.....           Baxter pays execs more than $8.5M to stick it out through pharma spinoff.....           Baxter pays execs more than $8.5M to stick it out through pharma spinoff.....           BioMarin shares climb on Shire takeover buzz.....           BioMarin shares climb on Shire takeover buzz.....           Eisai gets EMA nod for Lenvima just weeks after FDA approval.....           Eisai gets EMA nod for Lenvima just weeks after FDA approval.....           GSK's COPD treatment Encruse Ellipta gets Japanese approval.....           Novo Nordisk introduces hemophilia therapy Novoeight in US.....           Merck, American Diabetes Association partner to educate adults with diabetes.....           Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV.....           Takeda's NDA of Zafatek tablets gets approval in Japan to treat type 2 diabetes.....           What does Merck's $10B buyback plan say about pharma M&A?.....           Amgen doubles down on bid to block Novartis' biosimilar Neupogen.....           J&J CEO Gorsky sees 'new horizon' in China, despite slowing growth.....           Hey, European countries--join forces to bring down drug prices, WHO suggests.....           Dr. Reddy's shopping for deals up to $1B as it expands in injectable meds.....           The FDA's kinder, gentler attitude toward India hasn't stopped tough enforcement moves.....           AstraZeneca, Harvard Stem Cell Institute enter five-year diabetes research collaboration.....           Regulus' RG-012 gets orphan medicinal product designation in Europe to treat alport syndrome.....           Marinus gets FDA orphan drug status for ganaxolone to treat PCDH19 female epilepsy.....           FDA grants orphan drug status for CymaBay's MBX-8025 to treat HoFH.....           FDA approves Sanofi Pasteur's Quadracel vaccine for children four to six years of age.....           Teikoku gets FDA acknowledgment of receipt for Docetaxel Injection.....           Signum out-licenses SIG990 to Dermata to develop new topical treatment for rosacea.....           Agios gets FDA orphan drug status for AG-348 to treat pyruvate kinase deficiency.....           The $600 million man: Gilead CEO's stock gains push compensation way past estimates.....           Sun doubles in size as it completes Ranbaxy buyout.....           Cipla revs up for generic Sovaldi launch in India.....           Legal fallout from Valeant's failed Allergan siege? Experts debate.....           Amoun Pharma investors make another run at a $700M-plus sale.....           Geriatrics experts call for halt to Low-T consumer ads.....           Merck?s Phase III KEYNOTE-006 trial of melanoma drug Keytruda meets co-primary endpoints.....           Regene acquires new laboratory facilities in US.....           Biohaven enters into license deal for Catalent's Zydis ODT technology.....           Pharmax launches HLC Baby B and HLC Baby F probiotic supplements.....           NGM reports positive Phase II trial results of NGM282 in PBC patients.....           Emergent to advance development of next-generation anthrax vaccine NuThrax.....           Can-Fite inks distribution deal with Cipher for CF101 in Canada.....           Vertex reports Phase II trial results of VX-661 in combination with ivacaftor for cystic fibrosis.....           FDA lets Lilly's long-acting Zyprexa off the hook in patient deaths.....           AbbVie's $21B buyout puts Pharmacyclics execs in line for $4B payoff.....           UPDATED: GlaxoSmithKline tags 180 sales-and-admin jobs for cutting in NC.....           Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trial.....           Novo Nordisk unloads autoimmune project to Bristol-Myers.....           Which diseases are driving drug spending hikes? It's not just hep C.....           GSK, Cold Spring Harbor Lab to develop new drugs for obesity and diabetes.....           Mast Therapeutics to develop vepoloxamer to treat chronic heart failure.....           Takeda, Immunogen sign potential $440m drug development deal.....           Kamada's GvHD treatment AAT gets European orphan drug status.....           GenVec, TheraBiologics to develop new cancer therapeutics.....           UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ.....           Akorn expands ophthalmic portfolio with Phenylephrine HCl ophthalmic solution launch.....           AbbVie CEO pads $16M paycheck with $500K in jet travel.....           Gilead warns of fatal reaction to Sovaldi, Harvoni and heart drug.....           With MenB vaccine Bexsero in hand, GSK aims for a price deal in England.....           Daiichi Sankyo starts layoff drive with 16% cuts at HQ.....           Jury: Boy didn't prove J&J drug caused his breast growth.....           Regeneron chief nabs $42M, but he'll have to pay his own club fees this year.....           Boehringer reports positive results from Phase II psoriasis trial.....           Dilaforette gets FDA orphan drug status for sevuparin to treat sickle-cell disease.....           Biogen reports positive interim Phase Ib results of aducanumab to treat Alzheimer?s disease.....           Amgen seeks Japanese approval for Repatha to treat high cholesterol.....           Lilly partners with China's Innovent for new oncology therapies.....           Alzheon releases positive Phase I data of ALZ-801 to treat Alzheimer?s disease.....           ProMetic completes Phase Ib trial of PBI-4050 in CKD patients.....           Judge says Novartis can launch biosimilar of Amgen's Neupogen.....           Merck KGaA to tap Oschmann as new CEO, sources report.....           Hedge fund patent challenges are growing by the numbers, and drugmakers aren't happy.....           Biogen Alzheimer's drug reignites excitement.....           FDA hustles on opioid guidance to avoid budget meddling.....           AstraZeneca, Daiichi to jointly commercialize constipation drug Movantik in US.....           MedImmune, FAPESP to identify new early research projects in Brazil.....           Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases.....           ImmunoCellular, PharmaCell partner for European production of cancer immunotherapy ICT-107.....           AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy.....           Janssen Pharmaceuticals acquires ichorcumab developer XO1 Limited.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Freeze drying and alternative drying technologies for parenterals

28 January 2015 - Loughborough

Freeze drying - is there an alternative process technology to consider for your biopharmaceuticals?

A very successful one day meeting was held to look at the latest challenges and opportunities in the preservation of biopharmaceuticals. The meeting explored new developments in the established technology of freeze drying and discussed possible alternatives of spray drying, protein crystallisation and supercritical fluid drying of biopharmaceuticals.


Latest News
APS Parkinson's Disease: From Patient to Product
Venue: GSK, Ware Tuesday 19th May 2015. Parkinson’s Disease affects one in 500 people, with an estimated prevalence of 127,000 people in the UK with the condition. The use of medicines is a mainstay in treatment and can lead to an improvement in symptoms and movement. However, as the disease progresses, this presents challenges to patients, carers and prescribers in terms of what to prescribe and how it is administered. These challenges require science and clinical practice to come together to develop solutions to optimise treatment management for patients. This one-day meeting organised by the Age-Related Medicines Focus Group, will showcase the latest research in science and clinical practice pertaining to Parkinson’s Disease, present the perspectives of patients, and highlight regulatory perspectives in drug development.. The APS is grateful to GSK for their contribution to this event. As part of their 300th year celebrations, GSK are hosting a number of scientific events including this one.. For more details on the programme, fee's and to register, please visit us online here:. .
APS Inhaled Product Development Workshop: The science and strategy to facilitate development of an aerosolized medicine
Burleigh Court, Loughborough Thursday 11 and Friday 12 June 2015. The workshop is organised by the APS Inhalation Focus Group. Leaders: Eddie French, TEKH Consulting Ltd Martin Rowland, Pfizer WW Pharmaceutical sciences Purpose: To provide an overview of the basics and fundamentals of aerosol science and the broad spectrum of scientific disciplines involved in the process of inhaled product development. This workshop is aimed at helping scientists new to the area to understand the development area in which they work and to put their role into context. It will introduce them to ‘language’ of product development to facilitate involvement in project teams or understand customer needs. Target Audience: Project scientists from industry and academia, group supervisors, project managers and business development professionals who wish to increase their knowledge of both the basic science and the wider process of Inhaled Product Development. This course would be suitable for scientists from large and small pharma, academia and the Biotech and CRO sector. Format and Content: This workshop will be run for two days with presentations from academic and industrial experts who have considerable experience in the area of inhaled product development. This will be augmented by an interactive drug development case study to reinforce the key aspects of the course. Topics to be covered:. Overview of the process of developing an inhaled product from discovery to market. API: desirable physical and chemical properties for inhaled product development and methods for characterization. Formulations: for preclinical, clinical and the market. Inhalation analytics: overview of key tests and techniques. Devices: Device design and development, the device-formulation interface and the device–patient interface; the development of a combination product. Inhaled toxicology. Design of toxicology studies and how they are undertaken, formulation of test article and placebo for inhaled studies, understanding the output. Clinical studies: Design and implementation of Phase 1 to Phase3 clinical studies. Dose setting, how to dose range, SAD/MAD studies, end points and biomarkers, running a study, blinding requirements, understanding outputs and stopping rules etc. Regulatory aspects: Principles of developing products within the regulatory framework, relevant guidelines, and interactions with regulatory agencies Manufacturing and technology transfer: Scale up strategies, QbD, common problems and how to overcome them. Generic development and bioequivalence: In vitro - in vivo correlation, device strategies, guidelines. Cost of the workshop including all notes, meals and one night’s accommodation is included within the registration fee. To view the programme, course fees and to register, please visit us online at:. .
RPS Symposia: Advances in Technology Impacting the Pharmaceutical Industry
Friday 17th April University of Strathclyde Strathclyde Institute of Pharmacy and Biomedical Sciences Hamnett Wing. The APS would like to take the opportunity to inform you of the following symposia.. Advances in Technology Impacting the Pharmaceutical Industry will be held on 17 April 2015 at the University of Strathclyde.. Six top class pharmaceutical scientists and practitioners from across Europe will present innovations and discuss the implications of these advances on industrial pharmacy at this year's Scientific Symposium.. During this interesting and an interactive afternoon, you'll also have the chance to interact with your colleagues in the pharmaceutical industry and academia.. 13:00 Lunch 14:00 Introduction – Prof Jayne Lawrence, RPS Chief Scientist 14:15 Future Supply Chains for the Pharmaceutical Industry – a Collaborative Approach – Prof Clive Badman, GSK/University of Strathclyde 15:00 University of Strathclyde, CMAC capabilities – Prof Alistair Florence, SIPBS 15:30 New Medicine Evaluation, Scottish Medicines Consortium – Prof Angela Timoney 16:00 BREAK 16:15 Biotechnology in the Industry – Dr Christoph Schmidt, Ferring 16:45 Phar-IN – Competences for industrial pharmacy practice in biotechnology: Under/Postgraduate courses for the future – Prof De Paepe VuB, Belgium 17:15 CRUK Formulation unit – Prof Gavin Halbert 17:45 Closing remarks – Jean-Pierre Paccioni, President EIPG. FREE: Undergraduates, Post Graduates, Academic Staff £50 All other attendees. For more information, please visit:
Chairman's Blog
Your Academy moves on in 2015. ​. . I am delighted to reflect on the excellent work of the membership of APS in supporting the Focus Groups (FGs) and the new structures of Board and Extended Leadership Team set up at the AGM in 2014 to deliver on a strong programme for 2014-15. This is now available on the website. A report from the first of these events, APS Freeze drying and alternative drying technologies for parenterals, can be viewed on the APS website. The Board and the Extended Leadership Team which includes all the Focus Group Chairs are engaged in a very inclusive process and are working well. The first joint meeting of both in October looked at the programmes and the next in April will look at APS strategy and embed the needs of the focus groups within it. I can’t express strongly enough my thanks to all of you who make the APS work so well - please keep it up.. Each of the Focus groups is currently writing a one pager to highlight their hot topics and suggesting what can be done to work with the wider APS membership on them. These documents will link the day-to-day interests of the FGs and will be available for discussion at the April meeting. I am really keen to try and ensure that all hot topics of interest to our members are captured in the document that Mark McAllister and the FGs are preparing. If you are not a member of a focus group (? why not?) please send your ideas and suggestions to Carol O’ Connor ( or me and we will make sure they get discussed. APS is an organisation run for the members by the members and you all have a voice.. Much of the science which interests our members has the patient at its heart. We are often asked how does our particular science work for the benefit of the patient and I’m interested to hear your views. This theme was at the heart of our PharmSci conference in 2014 with a thought provoking lecture by the Science Chair, Linda Hakes. We will ask each Focus Group to consider if there is a strand or an aspect of their interest which could reflect this theme and we hope that this material will form the basis of articles we can use to publicise APS.. A really good example of our facilitation role is the current project funded by Innovate UK on paediatric formulation where we worked to engage the participants and will have a strong role to communicate the project results to the wider community.. Of course a lot of our other scientific interests do not link directly to patients but we do have communities which serve the food, cosmetics and materials sectors and it would be good to be able to make statements on their behalf too.. You will see from this blog I am trying to gain material to show the leading sectoral interest groups the added value which the Academy provides. It is important in these days of effective cost control that our value is clear and helpful and I will continue to work with you to ensure that our message is strong.. The programme for PharmSci has just gone up on the website and is a strong one focussed on innovation and led by this year’s Science Chair, David Jones from Queens University, Belfast. Last year we had a good range of exciting science in the poster session and I would encourage our young scientists and their supervisors to submit their abstracts in good time. There has been a real buzz about our conference each year and this year, in East Midlands Conference Centre, I’m sure it will be the same. I look forward to meeting you there.. Bill Dawson, Chair, APS.
Follow us
Upcoming Events
APS Bioequivalence of Orally Inhaled Drug Products: Joint Meeting with The Aerosol Society
30 March 2015
APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.